Online inquiry

IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12493MR)

This product GTTS-WQ12493MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC5AC gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001304359.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4586
UniProt ID P98088
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12493MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7430MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ8220MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ14592MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SAR-650984
GTTS-WQ9779MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ7470MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ1940MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ16009MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ8861MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW